Category

Combination Studies With The Vascular Disrupting Agent CA4P

 

Marketed By :  LAP LAMBERT Academic Publishing   Sold By :  Kamal Books International  
Delivery in :  10-12 Business Days

 
₹ 5,886

Availability: Out of stock

 

Delivery :

Product Out of Stock Subscription

(Notify me when this product is back in stock)

  • Product Description
 

This work represents studies carried out at Mount Vernon Hospital and UCL, and sponsored by Cancer Research UK, between 2003 and 2006. Phase I/II Clinical trial studies of the vascular disrupting agent Combretastatin A4 Phosphate (CA4P) are presented - in combination with cytotoxic chemotherapy (Paclitaxel and Carboplatin), and radioimmunotherapy. Dynamic Contrast Enhanced MRI data from the studies is presented and discussed, and a supporting immunohistochemistry correlation study of vascular markers is also presented.

Product Specifications
SKU :COC94432
Country of ManufactureIndia
Product BrandLAP LAMBERT Academic Publishing
Product Packaging InfoBox
In The Box1 Piece
0 Review(s)